Stay updated on Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.

Latest updates to the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page
- Check6 days agoChange DetectedRevision v3.5.0 was added to the history and v3.4.3 was removed.SummaryDifference0.1%

- Check13 days agoChange DetectedThe study record history shows the addition of revision v3.4.3 and the deletion of revision v3.4.2.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedAn addition shows Revision: v3.4.2 in the history. A government-funding lapse notice and the entry for Revision: v3.4.1 were removed from the history.SummaryDifference0.8%

- Check49 days agoChange DetectedAdded a site-wide notice about government funding and operating status (cc.nih.gov). Updated the record history to Revision: v3.4.1, replacing the previous v3.4.0 entry.SummaryDifference0.8%

- Check56 days agoChange DetectedThe history view now includes a glossary toggle and color-coded diffs (green for additions, red for deletions); release notes such as No FEAR Act Data and Revision: v3.4.0 are displayed as part of the changes.SummaryDifference1%

- Check70 days agoChange DetectedA new history entry for Revision: v3.3.4 was added after Revision: v3.3.3.SummaryDifference0.1%

Stay in the know with updates to Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab Plus Tislelizumab vs Durvalumab in cCRT Clinical Trial page.